509 related articles for article (PubMed ID: 31000408)
1. The neurological syndromes associated with glutamic acid decarboxylase antibodies.
Baizabal-Carvallo JF
J Autoimmun; 2019 Jul; 101():35-47. PubMed ID: 31000408
[TBL] [Abstract][Full Text] [Related]
2. Neurological Syndromes Associated with Anti-GAD Antibodies.
Dade M; Berzero G; Izquierdo C; Giry M; Benazra M; Delattre JY; Psimaras D; Alentorn A
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456344
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
5. Stiff Person syndrome and other anti-GAD-associated neurologic disorders.
Dayalu P; Teener JW
Semin Neurol; 2012 Nov; 32(5):544-9. PubMed ID: 23677666
[TBL] [Abstract][Full Text] [Related]
6. Immunology of stiff person syndrome and other GAD-associated neurological disorders.
Alexopoulos H; Dalakas MC
Expert Rev Clin Immunol; 2013 Nov; 9(11):1043-53. PubMed ID: 24168411
[TBL] [Abstract][Full Text] [Related]
7. Serum glutamate decarboxylase antibodies and neurological disorders: when to suspect their association?
Lacruz Ballester L; Fernandez-Fournier M; Puertas Muñoz I; Rodriguez Fraga O; Lastras Fernandez-Escandon C; Rodriguez de Rivera Garrido FJ; Alba Suarez EM; Tallon Barranco A
Neurol Sci; 2022 Jan; 43(1):633-641. PubMed ID: 33914193
[TBL] [Abstract][Full Text] [Related]
8. Glutamic acid decarboxylase antibody-associated neurological syndromes: Clinical and antibody characteristics and therapy response.
Madlener M; Strippel C; Thaler FS; Doppler K; Wandinger KP; Lewerenz J; Ringelstein M; Roessling R; Menge T; Wickel J; Kellingshaus C; Mues S; Kraft A; Linsa A; Tauber SC; Berg FT; Gerner ST; Paliantonis A; Finke A; Priller J; Schirotzek I; Süße M; Sühs KW; Urbanek C; Senel M; Sommer C; Kuempfel T; Pruess H; Fink GR; Leypoldt F; Melzer N; Malter MP;
J Neurol Sci; 2023 Feb; 445():120540. PubMed ID: 36608627
[TBL] [Abstract][Full Text] [Related]
9. Anti-glutamic acid decarboxylase antibody positive neurological syndromes.
Tohid H
Neurosciences (Riyadh); 2016 Jul; 21(3):215-22. PubMed ID: 27356651
[TBL] [Abstract][Full Text] [Related]
10. Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies.
Dalakas MC
Neurotherapeutics; 2022 Apr; 19(3):832-847. PubMed ID: 35084720
[TBL] [Abstract][Full Text] [Related]
11. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies.
Ali F; Rowley M; Jayakrishnan B; Teuber S; Gershwin ME; Mackay IR
J Autoimmun; 2011 Sep; 37(2):79-87. PubMed ID: 21680149
[TBL] [Abstract][Full Text] [Related]
12. [Stiff-person syndrome and other neurological disorders associated with anti-GAD antibodies].
Hijazi J; Bedat-Millet AL; Hannequin D
Rev Med Interne; 2010 Jan; 31(1):23-8. PubMed ID: 19828214
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.
Saiz A; Arpa J; Sagasta A; Casamitjana R; Zarranz JJ; Tolosa E; Graus F
Neurology; 1997 Oct; 49(4):1026-30. PubMed ID: 9339684
[TBL] [Abstract][Full Text] [Related]
14. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.
Dalakas MC
J Neurol; 2005 May; 252 Suppl 1():I19-25. PubMed ID: 15959668
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity.
Gresa-Arribas N; Ariño H; Martínez-Hernández E; Petit-Pedrol M; Sabater L; Saiz A; Dalmau J; Graus F
PLoS One; 2015; 10(3):e0121364. PubMed ID: 25774787
[TBL] [Abstract][Full Text] [Related]
16. GAD antibodies in neurological disorders - insights and challenges.
Graus F; Saiz A; Dalmau J
Nat Rev Neurol; 2020 Jul; 16(7):353-365. PubMed ID: 32457440
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune encephalitis associated with glutamic acid decarboxylase antibodies: a case series.
Incecik F; Herguner OM; Besen S; Yılmaz M
Acta Neurol Belg; 2018 Sep; 118(3):411-414. PubMed ID: 29349679
[TBL] [Abstract][Full Text] [Related]
18. Glutamic acid decarboxylase autoantibodies and neurological disorders.
Vianello M; Tavolato B; Giometto B
Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
[TBL] [Abstract][Full Text] [Related]
19. Anti-glutamic acid decarboxylase (GAD) positive cerebellar Ataxia with transitioning to progressive encephalomyelitis with rigidity and myoclonus (PERM), responsive to immunotherapy: A case report and review of literature.
Jazebi N; Rodrigo S; Gogia B; Shawagfeh A
J Neuroimmunol; 2019 Jul; 332():135-137. PubMed ID: 31015081
[TBL] [Abstract][Full Text] [Related]
20. Clinical spectrum of glutamic acid decarboxylase antibodies in a Taiwanese population.
Kuo YC; Lin CH
Eur J Neurol; 2019 Nov; 26(11):1384-1390. PubMed ID: 31132202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
